Although thyroid carcinoma is relatively uncommon, approximately 33,550 new cases will be diagnosed in the United States in 2007. It occurs 2 to 3 times more often in women than in men, and with the incidence increasing by 4% per year, it is currently the eighth most common malignancy diagnosed in women. Although it occurs more often in women, mortality rates are higher for men, probably because they are usually older at the time of diagnosis (65–69 years vs. 50–54 years in women). Interestingly, the incidence of thyroid carcinoma increased almost 240% between 1950 and 2000, but mortality rates decreased more than 44%. Important updates to the 2007 guidelines include revised criteria for categorizing disease, revised recommendation for thyroid-stimulating hormone–stimulated thyroglobulin in some cases, and expanded CT recommendations for anaplastic carcinoma.
For the most recent version of the guidelines, please visit NCCN.org
The mission of the H. Lee Moffitt Cancer Center & Research Institute is “to contribute to the prevention and cure of cancer.” All future plans for the Center in clinical care and research rest firmly on this principle and make possible the changes ahead.
Moffitt defines optimal cancer care with an interdisciplinary approach to the evaluation and treatment of cancer patients. In support of this philosophy, academic and clinical services are organized into 14 disease-oriented programs, with a team that includes medical oncologists, surgeons, radiation oncologists, nurses, social workers, pharmacists, and other support personnel.
Under the direction of William S. Dalton, PhD, MD (second photo on cover), Moffitt is focusing on an initiative called Total Cancer Care (TCC). TCC is an all-encompassing approach to treating cancer patients combining information technology, science, and clinical treatment to provide evidence-based guidelines that will improve care and outcomes. TCC involves studies of genetic predisposition, the impact of healthy lifestyles, quality improvement, survivorship, and molecular profiling—incorporating translational research at every step along the continuum. It will follow up with patients prospectively through screening, diagnosis, and treatment of cancer.
Additionally, one of Moffitt's newest research initiatives is to develop one of the largest tissue bio-repositories and relational databases in the country. The result of this combined molecular profiling and clinical response database will be to improve cancer prevention and treatment by using molecular technology.